A Phase 2 interventional study of Encorafenib and Cetuximab in BRAF V600E and Metastatic Colorectal Cancer, sponsored by Pierre Fabre Medicament. Completed at 34 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing encorafenib in Colorectal Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. encorafenib · Colorectal Neoplasms.
Among the 16 studies testing encorafenib in Colorectal Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2021, is one of 9 in phase 2, and was the 9th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →5 of the 16 studies testing encorafenib in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Vall d'Hebron Institute of Oncology · Sites in Spain
Ages 18+
Federation Francophone de Cancerologie Digestive · Sites in France
Ages 18+
Oslo University Hospital · Sites in Norway
Ages 18+
By country, each count listing its studies:
encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 2
First in 2011; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 95 across the 16 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pierre Fabre Medicament, one of the names counted as Pierre Fabre. Under that name alone:
Pierre Fabre Medicament is the lead sponsor of 73 studies on the registry; 6 are open to participants now.
Pierre Fabre has 4 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing encorafenib in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing encorafenib in Colorectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC), who have received prior systemic therapy.
Inclusion Criteria for Molecular Prescreening:
The following inclusion criteria must be met for a participant to be eligible to undergo molecular tumor prescreening:
Inclusion Criteria for Treatment Period:
The following inclusion criteria must be met for a participant to be eligible for this study:
NOTE: Other protocol defined Inclusion criteria may apply
Exclusion Criteria for Molecular Prescreening:
Participants meeting any of the following criteria are not eligible to undergo molecular tumor prescreening:
Exclusion Criteria for Treatment Period:
NOTE: Other protocol defined Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Safety Lead-in (SLI) phase: 28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly Randomized (Phase II) phase: 28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly
Drug: Encorafenib · Drug: Cetuximab
Randomized (Phase II) phase: Either irinotecan and cetuximab or FOLFIRI and cetuximab in 28 day cycles. Irinotecan and cetuximab: * irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks and * cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly OR FOLFIRI and cetuximab: * irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks * Folinic acid 400 mg/m² (120-minute infusion or to study site standards) or maximal dose tolerated in a prior regimen every 2 weeks * 5-FU 400 mg/m² initial dose bolus (not to exceed 15 minutes), then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46 to 48 hours) continuous infusion or maximal dose tolerated in a prior regimen every 2 weeks and * cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly
Drug: Encorafenib · Drug: Cetuximab · Drug: FOLFIRI
oral hard capsule
Also known as: Braftovi®, PF-07263896, W0090, LGX818, ONO-7702
intravenous infusion
Also known as: Erbitux®, C225
Combination of: irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion
Also known as: Folinic acid + Fluorouracil + Irinotecan
Safety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs)
DLT rate was estimated based on data from DLT-evaluable participants during the DLT-evaluation period (which is the first 28 days after the first dose of study intervention in the SLI) to assess the safety and tolerability of the doublet arm.
Time frame: Cycle 1 (up to 28 days)
Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Primary Completion Date
PFS was defined as the time from the date of randomization to the earliest documented disease progression (PD) as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause.
Time frame: From first dose to the earliest documented progression or death due to any cause, with a minimal participant's follow-up of 36 weeks and a maximum treatment exposure of 68 weeks
Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Final Analysis
PFS was defined as the time from the date of randomization to the earliest documented disease progression as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause.
Time frame: From first dose to the earliest documented PD or death due to any cause, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks
Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per BICR
cORR as determined by Blinded (to treatment received) Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per Investigator
cORR as determined by investigator assessment per RECIST version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Duration of Response (DOR) Per BICR
DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by BICR per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
Time frame: From time of response to the earliest documented PD or death due to underlying disease, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Duration of Response (DOR) Per Investigator
DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
Time frame: From time of response to the earliest documented PD or death due to underlying disease, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Overall Duration of Exposure to Study Treatment
Exposure to the study intervention was defined as the time interval between the actual date of first study intervention administration (included) and the actual date of last study intervention administration (included), i.e., as the quantity "date of last study intervention administration date of first study intervention administration + 1 day". Duration of exposure by treatment arm was computed as the maximum of all durations of exposure for each drug of the assigned regimen.
Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE is any untoward medical occurrence in a participant temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting TEAEs were reported in this outcome measure.
Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Number of Participants With Serious TEAEs
A serious TEAE is a TEAE that results in significant health consequences, such as death, hospitalization, or permanent disability. Number of participants reporting serious TEAEs were reported in this outcome measure.
Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant, whether or not considered related to the study intervention. Number of participants with dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure.
Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 68 weeks
Safety Lead-in Phase: Number of Participants With Clinically Notable Vital Sign Abnormalities
Clinically notable changes were defined as participants meeting the elevated or low values criterion compared to baseline. The criterion for clinically notable elevated values included: systolic blood pressure (BP): ≥ 160 millimeters of mercury (mmHg) and an increase ≥ 20 mmHg from baseline; diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; weight (kg) increase from baseline of ≥ 10 percent; body temperature \[degree Celsius (deg C)\] ≥ 37.5 deg C. The criterion for clinically notable low values included: systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; weight: ≥ 20 percent decrease from baseline; body temperature \[deg C\]: ≤ 36 °C.
Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Number of Participants With Clinically Notable Electrocardiogram (ECG) Values
Clinically notable ECG changes were defined as participants meeting the criterion for QT interval, QT interval corrected for heart rate using Fridericia's formula (QTcF), and heart rate compared to baseline. The criterion for QT interval and QTcF included: increase from baseline \> 30 msec (ms); increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms. The criterion for heart rate included: increase from baseline \> 25 percent to a value \> 100 beats per minute (bpm), decrease from baseline \> 25 percent and to a value \< 50 bpm.
Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters
Clinically notable shift was defined as a worsening from baseline by at least 2 Grades, or to Grade 3 or above based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.
Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters
Clinically notable shift was defined as a worsening from baseline by at least 2 Grades, or to Grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.
Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Number of Participants With Notable Dermatological Abnormalities
Dermatological examination was performed to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and primary melanoma, as these have been reported to occur with selective B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor treatment. \[1\] The category "Other" includes all other dermatological findings identified during examination (e.g. rash acneiform, skin hyperpigmentation...).
Time frame: From screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit, with a maximum treatment exposure of 111 weeks
Safety Lead-in Phase: Measurement of Performance Status Using the Eastern Co-operative Oncology Group (ECOG) Scale
The performance status of participants was assessed using the Eastern Co-operative Oncology Group (ECOG) scale. The scale was defined with the range from 0 to 5 with lower score mean a lower functional impairment, and a higher score (e.g. 5) corresponding to death.
Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 68 weeks
Safety Lead-in Phase: Evaluation of the Plasma Concentrations of Encorafenib
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
Time frame: First day of treatment (Cycle 1 Day I) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Safety Lead-in Phase: Evaluation of the Serum Concentrations of Cetuximab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Safety Lead-in Phase: Evaluation of the Area Under the Curve (AUC) Derived From Plasma Concentration of Encorafenib
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Safety Lead-in Phase: Evaluation of the Area Under the Curve (AUC) Derived From Serum Concentration of Cetuximab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Safety Lead-in Phase: Evaluation of the Maximum Concentration (Cmax) Derived From Plasma Concentration of Encorafenib
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Safety Lead-in Phase: Evaluation of the Maximum Concentration (Cmax) Derived From Serum Concentration of Cetuximab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Randomized Phase 2: Progression-free Survival (PFS) by Investigator
PFS was defined as the time from the date of randomization to the earliest documented date of PD as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
Time frame: From first dose to the earliest documented PD or death due to any cause, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks
Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per BICR
cORR as determined by Blinded (to treatment received) Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per Investigator
cORR as determined by investigator assessment per RECIST Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per BICR
DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by BICR per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
Time frame: From time of response to the earliest documented PD or death due to underlying disease, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks
Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per Investigator
DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
Time frame: From time of response to the earliest documented PD or death due to underlying disease, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks
Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per BICR
cDCR was defined as the proportion of participants with a confirmed Best Overall Response (BOR) of CR, PR or Stable Disease (SD), as determined by BICR per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per Investigator
cDCR was defined as the proportion of participants with a confirmed Best Overall Response (BOR) of CR, PR or Stable Disease (SD), as determined by investigator assesment per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per BICR
TTR for confirmed responses was defined for responders (CR or PR) as the time between the date of randomization until the first documented response of CR or PR as determined by BICR per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From day 1 until first documented response, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per Investigator
TTR for confirmed responses was defined for responders (CR or PR) as the time between the date of randomization until the first documented response of CR or PR as determined by investigator assessment per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From day 1 until first documented response, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Overall Survival (OS)
OS was defined as time from randomization until date of death due to any cause.
Time frame: From randomization to death due to any cause, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Overall Duration of Exposure to Study Treatment
Exposure to the study intervention was defined as the time interval between the actual date of first study intervention administration (included) and the actual date of last study intervention administration (included), i.e., as the quantity "date of last study intervention administration date of first study intervention administration + 1 day". Duration of exposure by treatment arm was computed as the maximum of all durations of exposure for each drug of the assigned regimen.
Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE is any untoward medical occurrence in a participant temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting TEAEs were reported in this outcome measure.
Time frame: Day 1 until 30 days after study intervention discontinuation
Randomized Phase 2: Number of Participants With Serious TEAEs
A serious TEAE is a TEAE that results in significant health consequences, such as death, hospitalization, or permanent disability. Number of participants reporting serious TEAEs were reported in this outcome measure.
Time frame: Day 1 until 30 days after study intervention discontinuation
Randomized Phase 2: Number of Participants With Clinically Notable Vital Sign Abnormalities
Clinically notable changes were defined as participants meeting the elevated or low values criterion compared to baseline. The criterion for clinically notable elevated values included: systolic blood pressure (BP): ≥ 160 millimeters of mercury (mmHg) and an increase ≥ 20 mmHg from baseline; diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; weight (kg) increase from baseline of ≥ 10 percent; body temperature \[degree Celsius (deg C)\] ≥ 37.5 deg C. The criterion for clinically notable low values included: systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; weight: ≥ 20 percent decrease from baseline; body temperature \[deg C\]: ≤ 36 °C.
Time frame: Day 1 until 30 days after last dose of study treatment
Randomized Phase 2: Number of Participants With Clinically Notable Electrocardiogram (ECG) Values
Clinically notable ECG changes were defined as participants meeting the criterion for QT interval, QT interval corrected for heart rate using Fridericia's formula (QTcF), and heart rate compared to baseline. The criterion for QT interval and QTcF included: increase from baseline \> 30 msec (ms); increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms. The criterion for heart rate included: increase from baseline \> 25 percent to a value \> 100 beats per minute (bpm), decrease from baseline \> 25 percent and to a value \< 50 bpm.
Time frame: Day 1 until 30 days after last dose of study treatment
Randomized Phase 2: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters
Clinically notable shift was defined as a worsening from baseline by at least 2 grades, or to grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.
Time frame: Day 1 until 30 days after last dose of study treatment
Randomized Phase 2: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters
Clinically notable shift was defined as a worsening from baseline by at least 2 grades, or to grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.
Time frame: Day 1 until 30 days after last dose of study treatment
Randomized Phase 2: Number of Participants With Notable Dermatological Abnormalities
Dermatological examination was performed to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and primary melanoma, as these have been reported to occur with selective B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor treatment. \[1\] All other dermatological findings identified during examination (e.g. rash acneiform, skin hyperpigmentation...).
Time frame: From screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Measurement of Performance Status Using the Eastern Co-operative Oncology Group (ECOG) Scale
The performance status of participants was assessed using the Eastern Co-operative Oncology Group (ECOG) scale. The scale was defined with the range from 0 to 5 with lower score mean a lower functional impairment, and a higher score (e.g. 5) corresponding to death. \[1\] Participants with no assessment of ECOG in the time frame.
Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Time to Definitive Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) Questionnaire Scores
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) questionnaire consisted of nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain, nausea and vomiting); and a global health and Quality of Life (QoL) scale. Each scale in the questionnaire was scored (0 to 100). High scores represented a high health/quality of life. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.
Time frame: Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Time to Definitive Deterioration in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire
The European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) consisted of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system consisted of five dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each was rated according to a five-point verbal rating scale (VRS): 1. no problems, 2. slight problems, 3. moderate problems, 4. severe problems and 5. extreme problems) and translated into a five-digit number that described the participant's health state. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.
Time frame: Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Time to Definitive Deterioration in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) Questionnaire
The Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) was a validated quality of life questionnaire for patient reported outcome assessment. The Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) consisted of 36 items, presented on a five-point Likert scale, in four domains of well-being (physical, emotional, social and functional) and the Colorectal Cancer Subscale. Higher score reflects a better quality of life. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.
Time frame: Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Randomized Phase 2: Evolution in the Patient Global Impression of Change (PGIC) Questionnaire
The Patient Global Impression of Change (PGIC) questionnaire is a scale often used to anchor and characterize participant reported outcome (PRO) findings. This consisted of questions that asked participants to evaluate their colorectal cancer symptoms since starting study intervention according to a seven-point verbal rating scale: 1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse. Completions of questionnaire are summarized per treatment group and study visits. Number of participants analyzed correspond to the actual number of participants who completed the questionnaire at the corresponding visit.
Time frame: Cycle 2 Day 1 until 30 days safety follow-up
Randomized Phase 2: Evaluation of the Plasma Concentrations of Encorafenib
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Randomized Phase 2: Evaluation of the Serum Concentrations of Cetuximab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Randomized Phase 2: Evaluation of the Area Under the Curve (AUC) Derived From Plasma Concentration of Encorafenib
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Randomized Phase 2: Evaluation of the Area Under the Curve (AUC) Derived From Serum Concentration of Cetuximab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Randomized Phase 2: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Randomized Phase 2: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Randomized Phase 2: Evaluation of the Maximum Concentration (Cmax) Derived From Plasma Concentration of Encorafenib
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Randomized Phase 2: Evaluation of the Maximum Concentration (Cmax) Derived From Serum Concentration of Cetuximab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
| Milestone | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|---|
| Started | 10 | 65 | 32 |
| Completed | 0 | 2 | 0 |
| Not completed | 10 | 63 | 32 |
| Withdrew: Adverse event | 1 | 6 | 5 |
| Withdrew: Progressive disease | 9 | 56 | 17 |
| Withdrew: Withdrawal by subject | 0 | 1 | 9 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 |
DLT rate was estimated based on data from DLT-evaluable participants during the DLT-evaluation period (which is the first 28 days after the first dose of study intervention in the SLI) to assess the safety and tolerability of the doublet arm.
| Participants | Safety Lead-in Phase: ENCO + CETUX |
|---|---|
| Safety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs) | 0 |
PFS was defined as the time from the date of randomization to the earliest documented disease progression (PD) as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Primary Completion Date | 4.2 (3.0 to 7.3) | 2.5 (1.3 to 4.3) |
PFS was defined as the time from the date of randomization to the earliest documented disease progression as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Final Analysis | 4.2 (3.0 to 6.9) | 2.5 (1.3 to 4.3) |
cORR as determined by Blinded (to treatment received) Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per BICR | 30 (6.7 to 65.2) |
cORR as determined by investigator assessment per RECIST version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per Investigator | 30 (6.7 to 65.2) |
DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by BICR per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
| months | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Duration of Response (DOR) Per BICR | 12.5 (3.6 to NA) |
DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
| months | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Duration of Response (DOR) Per Investigator | 7 (4.2 to NA) |
Exposure to the study intervention was defined as the time interval between the actual date of first study intervention administration (included) and the actual date of last study intervention administration (included), i.e., as the quantity "date of last study intervention administration date of first study intervention administration + 1 day". Duration of exposure by treatment arm was computed as the maximum of all durations of exposure for each drug of the assigned regimen.
| weeks | Safety Lead-in Phase: ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Overall Duration of Exposure to Study Treatment | 16.50 (4.0 to 110.9) |
A TEAE is any untoward medical occurrence in a participant temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting TEAEs were reported in this outcome measure.
| Participants | Safety Lead-in Phase: ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 10 |
A serious TEAE is a TEAE that results in significant health consequences, such as death, hospitalization, or permanent disability. Number of participants reporting serious TEAEs were reported in this outcome measure.
| Participants | Safety Lead-in Phase: ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Number of Participants With Serious TEAEs | 1 |
An AE is any untoward medical occurrence in a participant, whether or not considered related to the study intervention. Number of participants with dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure.
| Participants | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Dose interruptions | 3 |
| Dose modifications | 3 |
| Discontinuations due to AEs | 1 |
Clinically notable changes were defined as participants meeting the elevated or low values criterion compared to baseline. The criterion for clinically notable elevated values included: systolic blood pressure (BP): ≥ 160 millimeters of mercury (mmHg) and an increase ≥ 20 mmHg from baseline; diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; weight (kg) increase from baseline of ≥ 10 percent; body temperature \[degree Celsius (deg C)\] ≥ 37.5 deg C. The criterion for clinically notable low values included: systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; weight: ≥ 20 percent decrease from baseline; body temperature \[deg C\]: ≤ 36 °C.
| Participants | Safety Lead-in Phase: ENCO + CETUX |
|---|---|
| Systolic BP: >= 160 mmHg and an increase >= 20 mmHg from baseline | 1 |
| Diastolic BP: >= 100 mmHg and an increase >= 15 mmHg from baseline | 0 |
| Heart rate: >= 120 bpm with increase from baseline of >=15 bpm | 1 |
| Weight: increase from baseline of >= 10% | 0 |
| Body temperature [deg C]: >= 37.5 deg C | 2 |
Clinically notable ECG changes were defined as participants meeting the criterion for QT interval, QT interval corrected for heart rate using Fridericia's formula (QTcF), and heart rate compared to baseline. The criterion for QT interval and QTcF included: increase from baseline \> 30 msec (ms); increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms. The criterion for heart rate included: increase from baseline \> 25 percent to a value \> 100 beats per minute (bpm), decrease from baseline \> 25 percent and to a value \< 50 bpm.
| Participants | Safety Lead-in Phase: ENCO + CETUX |
|---|---|
| QT Interval - Increase from baseline > 30 ms | 4 |
| QT Interval - Increase from baseline > 60 ms | 0 |
| QT interval - New > 450 ms | 0 |
| QT interval - New > 480 ms | 0 |
| QT interval - New > 500 ms | 0 |
| QTcF Interval - Increase from baseline > 30 ms | 4 |
| QTcF Interval - Increase from baseline > 60 ms | 1 |
| QTcF Interval - New > 450 ms | 1 |
| QTcF Interval - New > 480 ms | 1 |
| QTcF Interval - New > 500 ms | 0 |
| Heart rate - Increase from baseline > 25% to a value > 100 bpm | 2 |
| Heart rate - Decrease from baseline > 25% and to a value < 50 bpm | 0 |
Clinically notable shift was defined as a worsening from baseline by at least 2 Grades, or to Grade 3 or above based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.
| Participants | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Hemoglobin (g/L) (Low) | 2 |
| Hemoglobin (g/L) (High) | 0 |
| Leukocytes (10/L) (Low) | 0 |
| Leukocytes (10/L) (High) | 0 |
| Neutrophils (10/L) (Low) | 0 |
| Platelets (10/L) (Low) | 0 |
| Lymphocytes (10/L) (Low) | 1 |
| Lymphocytes (10/L) (High) | 0 |
Clinically notable shift was defined as a worsening from baseline by at least 2 Grades, or to Grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.
| Participants | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Alanine Aminotransferase (IU/L) (High) | 0 |
| Albumin (g/L) (Low) | 0 |
| Alkaline Phosphatase (IU/L) (High) | 0 |
| Amylase (IU/L) (High) | 0 |
| Aspartate Aminotransferase (IU/L) (High) | 0 |
| Bilirubin (micromol/L) (High) | 0 |
| Calcium Corrected (mmol/L) (Low) | 1 |
| Calcium Corrected (mmol/L) (High) | 0 |
| Creatinine (umol/L) (High) | 1 |
| Creatine Kinase (IU/L) (High) | 0 |
| Glucose, Fasting (mmol/L) (Low) | 0 |
| Glucose, Fasting (mmol/L) (High) | 1 |
| Lipase (IU/L) (High) | 0 |
| Magnesium (mmol/L) (Low) | 0 |
| Magnesium (mmol/L) (High) | 0 |
| Potassium (mmol/L) (Low) | 0 |
| Potassium (mmol/L) (High) | 0 |
| Sodium (mmol/L) (Low) | 0 |
| Sodium (mmol/L) (High) | 0 |
| Troponin I (ug/L) (High) | 0 |
| Troponin T (ug/L) (High) | 0 |
| Urate (umol/L) (High) | 0 |
Dermatological examination was performed to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and primary melanoma, as these have been reported to occur with selective B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor treatment. \[1\] The category "Other" includes all other dermatological findings identified during examination (e.g. rash acneiform, skin hyperpigmentation...).
| Participants | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Keratoacanthoma | 1 |
| Squamous Cell Carcinoma | 0 |
| Primary Melanoma | 0 |
| Other [1] | 8 |
The performance status of participants was assessed using the Eastern Co-operative Oncology Group (ECOG) scale. The scale was defined with the range from 0 to 5 with lower score mean a lower functional impairment, and a higher score (e.g. 5) corresponding to death.
| Participants | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| 0 | 1 |
| 1 | 9 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
| nanogram/milliliter (ng/mL) | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 (pre-dose) | NA ± NA |
| Cycle 1 Day 1 (1 hour post-dose) | 1730 ± 113.2 |
| Cycle 1 Day 1 (2 hours post-dose) | 4120 ± 63.9 |
| Cycle 1 Day 1 (4 hours post-dose) | 4290 ± 28.2 |
| Cycle 1 Day 1 (6 hours post-dose) | 1970 ± 55.6 |
| Cycle 2 Day 1 (pre-dose) | 11.4 ± 104 |
| Cycle 2 Day 1 (1 hour post-dose) | 2720 ± 76.7 |
| Cycle 2 Day 1 (2 hours post-dose) | 2440 ± 42.8 |
| Cycle 2 Day 1 (4 hours post-dose) | 1070 ± 51.5 |
| Cycle 2 Day 1 (6 hours post-dose) | 512 ± 67.3 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
| ng/mL | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 (pre-dose) | NA ± NA |
| Cycle 1 Day 1 (1 hour post-dose) | 71800 ± 34.9 |
| Cycle 1 Day 1 (2 hours post-dose) | 161000 ± 40.6 |
| Cycle 1 Day 1 (4 hours post-dose) | 240000 ± 13.2 |
| Cycle 1 Day 1 (6 hours post-dose) | 220000 ± 14.1 |
| Cycle 2 Day 1 (pre-dose) | 47400 ± 25.2 |
| Cycle 2 Day 1 (1 hour post-dose) | 144000 ± 19.8 |
| Cycle 2 Day 1 (2 hours post-dose) | 198000 ± 15.6 |
| Cycle 2 Day 1 (4 hours post-dose) | 185000 ± 15.4 |
| Cycle 2 Day 1 (6 hours post-dose) | 199000 ± 7.7 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
| hour*nanogram/milliliter (h*ng/mL) | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 (AUC0-6) | 18200 ± 35.9 |
| Cycle 1 Day 1 (AUC0-tlast) | 18600 ± 34.9 |
| Cycle 2 Day 1 (AUC0-6) | 9760 ± 31.4 |
| Cycle 2 Day 1 (AUCtau) | 12500 ± 34.6 |
| Cycle 2 Day 1 (AUC0-tlast) | 9870 ± 30.8 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
| h*ng/mL | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 (AUC0-6) | 988000 ± 19 |
| Cycle 1 Day 1 (AUC0-tlast) | 1000000 ± 21.5 |
| Cycle 2 Day 1 (AUC0-6) | 987000 ± 13.1 |
| Cycle 2 Day 1 (AUC0-tlast) | 989000 ± 13.1 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
| ng/mL | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 | 5430 ± 33.7 |
| Cycle 2 Day 1 | 4210 ± 41.7 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
| ng/mL | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 | 244000 ± 11.1 |
| Cycle 2 Day 1 | 209000 ± 9.3 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
| ng/mL | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib | 11.4 ± 104 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
| ng/mL | Safety Lead-in Phase (SLI): ENCO + CETUX |
|---|---|
| Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab | 47400 ± 25.2 |
PFS was defined as the time from the date of randomization to the earliest documented date of PD as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Progression-free Survival (PFS) by Investigator | 4.2 (4.0 to 5.5) | 2.5 (1.3 to 3.9) |
cORR as determined by Blinded (to treatment received) Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per BICR | 23.1 (13.5 to 35.2) | 6.3 (0.8 to 20.8) |
cORR as determined by investigator assessment per RECIST Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per Investigator | 27.7 (17.3 to 40.2) | 6.3 (0.8 to 20.8) |
DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by BICR per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per BICR | 5.6 (2.8 to 18.0) | NA (NA to NA) |
DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per Investigator | 4.0 (2.8 to 6.9) | NA (NA to NA) |
cDCR was defined as the proportion of participants with a confirmed Best Overall Response (BOR) of CR, PR or Stable Disease (SD), as determined by BICR per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per BICR | 75.4 (63.1 to 85.2) | 28.1 (13.7 to 46.7) |
cDCR was defined as the proportion of participants with a confirmed Best Overall Response (BOR) of CR, PR or Stable Disease (SD), as determined by investigator assesment per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per Investigator | 78.5 (66.5 to 87.7) | 37.5 (21.1 to 56.3) |
TTR for confirmed responses was defined for responders (CR or PR) as the time between the date of randomization until the first documented response of CR or PR as determined by BICR per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per BICR | 1.4 (1.3 to 1.6) | 1.5 (1.4 to NA) |
TTR for confirmed responses was defined for responders (CR or PR) as the time between the date of randomization until the first documented response of CR or PR as determined by investigator assessment per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per Investigator | 1.5 (1.3 to 2.7) | 1.6 (1.4 to NA) |
OS was defined as time from randomization until date of death due to any cause.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Overall Survival (OS) | 11.9 (8.2 to 16.6) | 8.2 (5.2 to 12.4) |
Exposure to the study intervention was defined as the time interval between the actual date of first study intervention administration (included) and the actual date of last study intervention administration (included), i.e., as the quantity "date of last study intervention administration date of first study intervention administration + 1 day". Duration of exposure by treatment arm was computed as the maximum of all durations of exposure for each drug of the assigned regimen.
| weeks | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Overall Duration of Exposure to Study Treatment | 18.90 (1.0 to 116.3) | 8.00 (2.0 to 22.6) |
A TEAE is any untoward medical occurrence in a participant temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting TEAEs were reported in this outcome measure.
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 65 | 27 |
A serious TEAE is a TEAE that results in significant health consequences, such as death, hospitalization, or permanent disability. Number of participants reporting serious TEAEs were reported in this outcome measure.
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Number of Participants With Serious TEAEs | 20 | 5 |
Clinically notable changes were defined as participants meeting the elevated or low values criterion compared to baseline. The criterion for clinically notable elevated values included: systolic blood pressure (BP): ≥ 160 millimeters of mercury (mmHg) and an increase ≥ 20 mmHg from baseline; diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; weight (kg) increase from baseline of ≥ 10 percent; body temperature \[degree Celsius (deg C)\] ≥ 37.5 deg C. The criterion for clinically notable low values included: systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; weight: ≥ 20 percent decrease from baseline; body temperature \[deg C\]: ≤ 36 °C.
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Systolic BP: >= 160 mmHg and an increase >= 20 mmHg from baseline | 2 | 0 |
| Diastolic BP: >= 100 mmHg and an increase >= 15 mmHg from baseline | 1 | 0 |
| Heart rate: >= 120 bpm with increase from baseline of >=15 bpm | 2 | 1 |
| Weight: increase from baseline of >= 10% | 6 | 1 |
| Body temperature [deg C]: >= 37.5 deg C | 7 | 1 |
| Systolic BP: <= 90 mmHg with decrease from baseline of >= 20 mmHg | 7 | 0 |
| Diastolic BP: <= 50 mmHg with decrease from baseline of >= 15 mmHg | 3 | 0 |
| Heart rate: <= 50 bpm with decrease from baseline of >= 15 bpm | 1 | 0 |
| Weight: >= 20% decrease from baseline | 0 | 0 |
| Body temperature [deg C]: <= 36 deg C | 32 | 7 |
Clinically notable ECG changes were defined as participants meeting the criterion for QT interval, QT interval corrected for heart rate using Fridericia's formula (QTcF), and heart rate compared to baseline. The criterion for QT interval and QTcF included: increase from baseline \> 30 msec (ms); increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms. The criterion for heart rate included: increase from baseline \> 25 percent to a value \> 100 beats per minute (bpm), decrease from baseline \> 25 percent and to a value \< 50 bpm.
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| QT Interval - Increase from baseline > 30 ms | 37 | 2 |
| QT Interval - Increase from baseline > 60 ms | 7 | 1 |
| QT interval - New > 450 ms | 2 | 1 |
| QT interval - New > 480 ms | 1 | 0 |
| QT interval - New > 500 ms | 0 | 0 |
| QTcF Interval - Increase from baseline > 30 ms | 24 | 1 |
| QTcF Interval - Increase from baseline > 60 ms | 2 | 1 |
| QTcF Interval - New > 450 ms | 9 | 2 |
| QTcF Interval - New > 480 ms | 0 | 1 |
| QTcF Interval - New > 500 ms | 0 | 1 |
| Heart rate - Increase from baseline > 25% to a value > 100 bpm | 10 | 9 |
| Heart rate - Decrease from baseline > 25% and to a value < 50 bpm | 1 | 0 |
Clinically notable shift was defined as a worsening from baseline by at least 2 grades, or to grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Hemoglobin (g/L) (Low) | 7 | 7 |
| Hemoglobin (g/L) (High) | 0 | 0 |
| Leukocytes (10/L) (Low) | 2 | 13 |
| Leukocytes (10/L) (High) | 0 | 0 |
| Neutrophils (10/L) (Low) | 4 | 11 |
| Platelets (10/L) (Low) | 3 | 0 |
| Lymphocytes (10/L) (Low) | 11 | 8 |
| Lymphocytes (10/L) (High) | 1 | 1 |
Clinically notable shift was defined as a worsening from baseline by at least 2 grades, or to grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Alanine Aminotransferase (IU/L) (High) | 3 | 0 |
| Albumin (g/L) (Low) | 3 | 1 |
| Alkaline Phosphatase (IU/L) (High) | 3 | 0 |
| Amylase (IU/L) (High) | 1 | 1 |
| Aspartate Aminotransferase (IU/L) (High) | 2 | 0 |
| Bilirubin (micromol/L) (High) | 2 | 1 |
| Calcium Corrected (mmol/L) (Low) | 2 | 0 |
| Calcium Corrected (mmol/L) (High) | 1 | 0 |
| Creatinine (umol/L) (High) | 6 | 3 |
| Creatine Kinase (IU/L) (High) | 0 | 1 |
| Glucose, Fasting (mmol/L) (Low) | 1 | 0 |
| Glucose, Fasting (mmol/L) (High) | 6 | 0 |
| Lipase (IU/L) (High) | 7 | 2 |
| Magnesium (mmol/L) (Low) | 4 | 0 |
| Magnesium (mmol/L) (High) | 1 | 0 |
| Potassium (mmol/L) (Low) | 0 | 0 |
| Potassium (mmol/L) (High) | 4 | 0 |
| Sodium (mmol/L) (Low) | 5 | 3 |
| Sodium (mmol/L) (High) | 0 | 0 |
| Troponin I (ug/L) (High) | 0 | 0 |
| Troponin T (ug/L) (High) | 0 | 0 |
| Urate (umol/L) (High) | 2 | 0 |
Dermatological examination was performed to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and primary melanoma, as these have been reported to occur with selective B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor treatment. \[1\] All other dermatological findings identified during examination (e.g. rash acneiform, skin hyperpigmentation...).
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Keratoacanthoma | 0 | 0 |
| Squamous Cell Carcinoma | 0 | 0 |
| Primary Melanoma | 0 | 0 |
| Other [1] | 39 | 0 |
The performance status of participants was assessed using the Eastern Co-operative Oncology Group (ECOG) scale. The scale was defined with the range from 0 to 5 with lower score mean a lower functional impairment, and a higher score (e.g. 5) corresponding to death. \[1\] Participants with no assessment of ECOG in the time frame.
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| 0 | 17 | 5 |
| 1 | 46 | 15 |
| 2 | 0 | 1 |
| NA [1] | 2 | 6 |
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) questionnaire consisted of nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain, nausea and vomiting); and a global health and Quality of Life (QoL) scale. Each scale in the questionnaire was scored (0 to 100). High scores represented a high health/quality of life. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Time to Definitive Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) Questionnaire Scores | NA (7.3 to NA) | 2.5 (1.6 to NA) |
The European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) consisted of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system consisted of five dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each was rated according to a five-point verbal rating scale (VRS): 1. no problems, 2. slight problems, 3. moderate problems, 4. severe problems and 5. extreme problems) and translated into a five-digit number that described the participant's health state. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Time to Definitive Deterioration in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire | 8.0 (5.6 to NA) | 4.2 (1.6 to 5.9) |
The Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) was a validated quality of life questionnaire for patient reported outcome assessment. The Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) consisted of 36 items, presented on a five-point Likert scale, in four domains of well-being (physical, emotional, social and functional) and the Colorectal Cancer Subscale. Higher score reflects a better quality of life. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.
| months | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Randomized Phase 2: Time to Definitive Deterioration in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) Questionnaire | 22.1 (6.0 to NA) | 2.5 (1.4 to 5.9) |
The Patient Global Impression of Change (PGIC) questionnaire is a scale often used to anchor and characterize participant reported outcome (PRO) findings. This consisted of questions that asked participants to evaluate their colorectal cancer symptoms since starting study intervention according to a seven-point verbal rating scale: 1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse. Completions of questionnaire are summarized per treatment group and study visits. Number of participants analyzed correspond to the actual number of participants who completed the questionnaire at the corresponding visit.
| Participants | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|
| Cycle 2 Day 1 — Very much improved | 7 | 0 |
| Cycle 2 Day 1 — Much improved | 29 | 3 |
| Cycle 2 Day 1 — Minimally improved | 15 | 9 |
| Cycle 2 Day 1 — No change | 9 | 5 |
| Cycle 2 Day 1 — Minimally worse | 1 | 0 |
| Cycle 2 Day 1 — Much worse | 0 | 0 |
| Cycle 3 Day 1 — Very much improved | 14 | 0 |
| Cycle 3 Day 1 — Much improved | 22 | 3 |
| Cycle 3 Day 1 — Minimally improved | 12 | 4 |
| Cycle 3 Day 1 — No change | 3 | 3 |
| Cycle 3 Day 1 — Minimally worse | 2 | 0 |
| Cycle 3 Day 1 — Much worse | 0 | 1 |
| Cycle 4 Day 1 — Very much improved | 11 | 0 |
| Cycle 4 Day 1 — Much improved | 23 | 2 |
| Cycle 4 Day 1 — Minimally improved | 5 | 2 |
| Cycle 4 Day 1 — No change | 4 | 2 |
| Cycle 4 Day 1 — Minimally worse | 0 | 0 |
| Cycle 4 Day 1 — Much worse | 0 | 0 |
| Cycle 5 Day 1 — Very much improved | 11 | 0 |
| Cycle 5 Day 1 — Much improved | 14 | 1 |
| Cycle 5 Day 1 — Minimally improved | 4 | 0 |
| Cycle 5 Day 1 — No change | 4 | 1 |
| Cycle 5 Day 1 — Minimally worse | 0 | 0 |
| Cycle 5 Day 1 — Much worse | 0 | 0 |
| Cycle 6 Day 1 — Very much improved | 9 | 0 |
| Cycle 6 Day 1 — Much improved | 10 | 1 |
| Cycle 6 Day 1 — Minimally improved | 4 | 0 |
| Cycle 6 Day 1 — No change | 2 | 0 |
| Cycle 6 Day 1 — Minimally worse | 0 | 0 |
| Cycle 6 Day 1 — Much worse | 0 | 0 |
| Cycle 7 Day 1 — Very much improved | 7 | 0 |
| Cycle 7 Day 1 — Much improved | 7 | 0 |
| Cycle 7 Day 1 — Minimally improved | 2 | 0 |
| Cycle 7 Day 1 — No change | 1 | 0 |
| Cycle 7 Day 1 — Minimally worse | 0 | 0 |
| Cycle 7 Day 1 — Much worse | 0 | 0 |
| Cycle 8 Day 1 — Very much improved | 9 | 0 |
| Cycle 8 Day 1 — Much improved | 5 | 0 |
| Cycle 8 Day 1 — Minimally improved | 2 | 0 |
| Cycle 8 Day 1 — No change | 1 | 0 |
| Cycle 8 Day 1 — Minimally worse | 0 | 0 |
| Cycle 8 Day 1 — Much worse | 0 | 0 |
| Cycle 9 Day 1 — Very much improved | 9 | 0 |
| Cycle 9 Day 1 — Much improved | 4 | 0 |
| Cycle 9 Day 1 — Minimally improved | 1 | 0 |
| Cycle 9 Day 1 — No change | 0 | 0 |
| Cycle 9 Day 1 — Minimally worse | 0 | 0 |
| Cycle 9 Day 1 — Much worse | 0 | 0 |
| Cycle 10 Day 1 — Very much improved | 4 | 0 |
| Cycle 10 Day 1 — Much improved | 6 | 0 |
| Cycle 10 Day 1 — Minimally improved | 2 | 0 |
| Cycle 10 Day 1 — No change | 1 | 0 |
| Cycle 10 Day 1 — Minimally worse | 0 | 0 |
| Cycle 10 Day 1 — Much worse | 0 | 0 |
| Cycle 11 Day 1 — Very much improved | 3 | 0 |
| Cycle 11 Day 1 — Much improved | 8 | 0 |
| Cycle 11 Day 1 — Minimally improved | 0 | 0 |
| Cycle 11 Day 1 — No change | 2 | 0 |
| Cycle 11 Day 1 — Minimally worse | 0 | 0 |
| Cycle 11 Day 1 — Much worse | 0 | 0 |
| Cycle 12 Day 1 — Very much improved | 5 | 0 |
| Cycle 12 Day 1 — Much improved | 6 | 0 |
| Cycle 12 Day 1 — Minimally improved | 0 | 0 |
| Cycle 12 Day 1 — No change | 2 | 0 |
| Cycle 12 Day 1 — Minimally worse | 0 | 0 |
| Cycle 12 Day 1 — Much worse | 0 | 0 |
| Cycle 13 Day 1 — Very much improved | 3 | 0 |
| Cycle 13 Day 1 — Much improved | 4 | 0 |
| Cycle 13 Day 1 — Minimally improved | 1 | 0 |
| Cycle 13 Day 1 — No change | 0 | 0 |
| Cycle 13 Day 1 — Minimally worse | 0 | 0 |
| Cycle 13 Day 1 — Much worse | 0 | 0 |
| Cycle 14 Day 1 — Very much improved | 1 | 0 |
| Cycle 14 Day 1 — Much improved | 4 | 0 |
| Cycle 14 Day 1 — Minimally improved | 1 | 0 |
| Cycle 14 Day 1 — No change | 0 | 0 |
| Cycle 14 Day 1 — Minimally worse | 0 | 0 |
| Cycle 14 Day 1 — Much worse | 0 | 0 |
| Cycle 15 Day 1 — Very much improved | 1 | 0 |
| Cycle 15 Day 1 — Much improved | 4 | 0 |
| Cycle 15 Day 1 — Minimally improved | 0 | 0 |
| Cycle 15 Day 1 — No change | 1 | 0 |
| Cycle 15 Day 1 — Minimally worse | 0 | 0 |
| Cycle 15 Day 1 — Much worse | 0 | 0 |
| Cycle 16 Day 1 — Very much improved | 2 | 0 |
| Cycle 16 Day 1 — Much improved | 2 | 0 |
| Cycle 16 Day 1 — Minimally improved | 1 | 0 |
| Cycle 16 Day 1 — No change | 0 | 0 |
| Cycle 16 Day 1 — Minimally worse | 0 | 0 |
| Cycle 16 Day 1 — Much worse | 0 | 0 |
| Cycle 17 Day 1 — Very much improved | 2 | 0 |
| Cycle 17 Day 1 — Much improved | 2 | 0 |
| Cycle 17 Day 1 — Minimally improved | 0 | 0 |
| Cycle 17 Day 1 — No change | 1 | 0 |
| Cycle 17 Day 1 — Minimally worse | 0 | 0 |
| Cycle 17 Day 1 — Much worse | 0 | 0 |
| Cycle 18 Day 1 — Very much improved | 1 | 0 |
| Cycle 18 Day 1 — Much improved | 3 | 0 |
| Cycle 18 Day 1 — Minimally improved | 1 | 0 |
| Cycle 18 Day 1 — No change | 0 | 0 |
| Cycle 18 Day 1 — Minimally worse | 0 | 0 |
| Cycle 18 Day 1 — Much worse | 0 | 0 |
| Cycle 19 Day 1 — Very much improved | 2 | 0 |
| Cycle 19 Day 1 — Much improved | 3 | 0 |
| Cycle 19 Day 1 — Minimally improved | 0 | 0 |
| Cycle 19 Day 1 — No change | 0 | 0 |
| Cycle 19 Day 1 — Minimally worse | 0 | 0 |
| Cycle 19 Day 1 — Much worse | 0 | 0 |
| Cycle 20 Day 1 — Very much improved | 1 | 0 |
| Cycle 20 Day 1 — Much improved | 3 | 0 |
| Cycle 20 Day 1 — Minimally improved | 1 | 0 |
| Cycle 20 Day 1 — No change | 0 | 0 |
| Cycle 20 Day 1 — Minimally worse | 0 | 0 |
| Cycle 20 Day 1 — Much worse | 0 | 0 |
| Cycle 21 Day 1 — Very much improved | 0 | 0 |
| Cycle 21 Day 1 — Much improved | 4 | 0 |
| Cycle 21 Day 1 — Minimally improved | 1 | 0 |
| Cycle 21 Day 1 — No change | 0 | 0 |
| Cycle 21 Day 1 — Minimally worse | 0 | 0 |
| Cycle 21 Day 1 — Much worse | 0 | 0 |
| Cycle 22 Day 1 — Very much improved | 2 | 0 |
| Cycle 22 Day 1 — Much improved | 1 | 0 |
| Cycle 22 Day 1 — Minimally improved | 1 | 0 |
| Cycle 22 Day 1 — No change | 0 | 0 |
| Cycle 22 Day 1 — Minimally worse | 0 | 0 |
| Cycle 22 Day 1 — Much worse | 0 | 0 |
| Cycle 23 Day 1 — Very much improved | 0 | 0 |
| Cycle 23 Day 1 — Much improved | 3 | 0 |
| Cycle 23 Day 1 — Minimally improved | 0 | 0 |
| Cycle 23 Day 1 — No change | 0 | 0 |
| Cycle 23 Day 1 — Minimally worse | 0 | 0 |
| Cycle 23 Day 1 — Much worse | 0 | 0 |
| Cycle 24 Day 1 — Very much improved | 1 | 0 |
| Cycle 24 Day 1 — Much improved | 2 | 0 |
| Cycle 24 Day 1 — Minimally improved | 0 | 0 |
| Cycle 24 Day 1 — No change | 0 | 0 |
| Cycle 24 Day 1 — Minimally worse | 0 | 0 |
| Cycle 24 Day 1 — Much worse | 0 | 0 |
| Cycle 25 Day 1 — Very much improved | 0 | 0 |
| Cycle 25 Day 1 — Much improved | 1 | 0 |
| Cycle 25 Day 1 — Minimally improved | 0 | 0 |
| Cycle 25 Day 1 — No change | 0 | 0 |
| Cycle 25 Day 1 — Minimally worse | 0 | 0 |
| Cycle 25 Day 1 — Much worse | 0 | 0 |
| Cycle 26 Day 1 — Very much improved | 0 | 0 |
| Cycle 26 Day 1 — Much improved | 1 | 0 |
| Cycle 26 Day 1 — Minimally improved | 0 | 0 |
| Cycle 26 Day 1 — No change | 0 | 0 |
| Cycle 26 Day 1 — Minimally worse | 0 | 0 |
| Cycle 26 Day 1 — Much worse | 0 | 0 |
| Cycle 27 Day 1 — Very much improved | 1 | 0 |
| Cycle 27 Day 1 — Much improved | 0 | 0 |
| Cycle 27 Day 1 — Minimally improved | 0 | 0 |
| Cycle 27 Day 1 — No change | 0 | 0 |
| Cycle 27 Day 1 — Minimally worse | 0 | 0 |
| Cycle 27 Day 1 — Much worse | 0 | 0 |
| Cycle 28 Day 1 — Very much improved | 0 | 0 |
| Cycle 28 Day 1 — Much improved | 1 | 0 |
| Cycle 28 Day 1 — Minimally improved | 0 | 0 |
| Cycle 28 Day 1 — No change | 0 | 0 |
| Cycle 28 Day 1 — Minimally worse | 0 | 0 |
| Cycle 28 Day 1 — Much worse | 0 | 0 |
| End of Treatment — Very much improved | 10 | 0 |
| End of Treatment — Much improved | 15 | 3 |
| End of Treatment — Minimally improved | 11 | 7 |
| End of Treatment — No change | 7 | 2 |
| End of Treatment — Minimally worse | 3 | 1 |
| End of Treatment — Much worse | 3 | 1 |
| Safety Follow-up — Very much improved | 3 | 0 |
| Safety Follow-up — Much improved | 7 | 1 |
| Safety Follow-up — Minimally improved | 3 | 1 |
| Safety Follow-up — No change | 2 | 1 |
| Safety Follow-up — Minimally worse | 1 | 0 |
| Safety Follow-up — Much worse | 0 | 2 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
| ng/mL | Randomized Phase: ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 (pre-dose) | NA ± NA |
| Cycle 1 Day 1 (1 hour post-dose) | 2490 ± 242.8 |
| Cycle 1 Day 1 (2 hours post-dose) | 3850 ± 108.5 |
| Cycle 1 Day 1 (4 hours post-dose) | 3330 ± 59.4 |
| Cycle 1 Day 1 (6 hours post-dose) | 2180 ± 70.1 |
| Cycle 2 Day 1 (pre-dose) | NA ± NA |
| Cycle 2 Day 1 (1 hour post-dose) | 1290 ± 224.3 |
| Cycle 2 Day 1 (2 hours post-dose) | 2490 ± 41.7 |
| Cycle 2 Day 1 (4 hours post-dose) | 976 ± 35.4 |
| Cycle 2 Day 1 (6 hours post-dose) | 461 ± 42.3 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
| ng/mL | Randomized Phase: ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 (pre-dose) | NA ± NA |
| Cycle 1 Day 1 (1 hour post-dose) | 82500 ± 27.2 |
| Cycle 1 Day 1 (2 hours post-dose) | 175000 ± 22.7 |
| Cycle 1 Day 1 (4 hours post-dose) | 222000 ± 30.9 |
| Cycle 1 Day 1 (6 hours post-dose) | 207000 ± 25.4 |
| Cycle 2 Day 1 (pre-dose) | 53000 ± 40.6 |
| Cycle 2 Day 1 (1 hour post-dose) | 170000 ± 28.4 |
| Cycle 2 Day 1 (2 hours post-dose) | 192000 ± 26.9 |
| Cycle 2 Day 1 (4 hours post-dose) | 195000 ± 21.1 |
| Cycle 2 Day 1 (6 hours post-dose) | 184000 ± 26.5 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
| h*ng/mL | Randomized Phase: ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 (AUC0-6) | 18400 ± 55.7 |
| Cycle 1 Day 1 (AUC0-tlast) | 18800 ± 54.7 |
| Cycle 2 Day 1 (AUC0-6) | 8670 ± 15 |
| Cycle 2 Day 1 (AUCtau) | 10800 ± 14.3 |
| Cycle 2 Day 1 (AUC0-tlast) | 8710 ± 14.7 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
| hour*nanogram/milliliter | Randomized Phase: ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 (AUC0-6) | 927000 ± 21.5 |
| Cycle 1 Day 1 (AUC0-tlast) | 927000 ± 21.5 |
| Cycle 2 Day 1 (AUC0-6) | 994000 ± 26.4 |
| Cycle 2 Day 1 (AUC0-tlast) | 990000 ± 26.8 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
| ng/mL | Randomized Phase: ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 | NA ± NA |
| Cycle 2 Day 1 | 7.75 ± 96.1 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
| ng/mL | Randomized Phase: ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 | NA ± NA |
| Cycle 2 Day 1 | 53000 ± 40.6 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.
| ng/mL | Randomized Phase: ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 | 5610 ± 48.7 |
| Cycle 2 Day 1 | 3700 ± 27.9 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.
| ng/mL | Randomized Phase: ENCO + CETUX |
|---|---|
| Cycle 1 Day 1 | 230000 ± 28.1 |
| Cycle 2 Day 1 | 197000 ± 27.5 |
Collected over Adverse Events (AE) were collected from when the participant first provided informed consent until 30 days after study intervention discontinuation. For SLI: ENCO + CETUX: maximum treatment exposure of 111 weeks; for Randomized Phase: ENCO + CETUX and Randomized Phase: Control Arm: maximum treatment exposure of 116 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Lead-in Phase: ENCO + CETUX | 9/10 (90%) | 1/10 (10%) | 9/10 (90%) |
| Randomized Phase: ENCO + CETUX | 44/65 (67.7%) | 20/65 (30.8%) | 45/65 (69.2%) |
| Randomized Phase: Control Arm | 24/32 (75%) | 5/32 (15.6%) | 22/32 (68.8%) |
| Event | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|---|
| Cerebral infarctionNervous system disorders | 1/10 | 1/65 | 0/32 |
| Intestinal obstructionGastrointestinal disorders | 0/10 | 6/65 | 2/32 |
| Gastrointestinal perforationGastrointestinal disorders | 0/10 | 0/65 | 2/32 |
| Abdominal painGastrointestinal disorders | 0/10 | 0/65 | 1/32 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 0/65 | 1/32 |
| Gastrointestinal infectionInfections and infestations | 0/10 | 0/65 | 1/32 |
| Pneumonia aspirationInfections and infestations | 0/10 | 0/65 | 1/32 |
| Septic shockInfections and infestations | 0/10 | 0/65 | 1/32 |
| Pericardial effusionCardiac disorders | 0/10 | 2/65 | 0/32 |
| PneumoniaInfections and infestations | 0/10 | 2/65 | 0/32 |
| Event | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm |
|---|---|---|---|
| MalaiseGeneral disorders | 7/10 | 9/65 | 2/32 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 5/10 | 10/65 | 4/32 |
| Decreased appetiteMetabolism and nutrition disorders | 5/10 | 11/65 | 6/32 |
| HyperglycaemiaMetabolism and nutrition disorders | 5/10 | 8/65 | 0/32 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/10 | 9/65 | 1/32 |
| AnaemiaBlood and lymphatic system disorders | 5/10 | 21/65 | 10/32 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/10 | 14/65 | 0/32 |
| White blood cell count decreasedInvestigations | 0/10 | 5/65 | 13/32 |
| Weight decreasedInvestigations | 4/10 | 16/65 | 5/32 |
| DiarrhoeaGastrointestinal disorders | 4/10 | 10/65 | 9/32 |
| Age, Continuous(years) | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm | Total |
|---|---|---|---|---|
| Mean | 57.90 ± 13.15 | 53.52 ± 14.00 | 54.56 ± 14.78 | 54.04 ± 13.74 |
| Age, Customized(Participants) | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm | Total |
|---|---|---|---|---|
| Age Group — <65 | 6 | 49 | 19 | 74 |
| Age Group — 65-74 | 4 | 10 | 13 | 27 |
| Age Group — >= 75 | 0 | 6 | 0 | 6 |
| Sex: Female, Male(Participants) | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm | Total |
|---|---|---|---|---|
| Female | 3 | 31 | 21 | 55 |
| Male | 7 | 34 | 11 | 52 |
| Race (NIH/OMB)(Participants) | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 10 | 65 | 32 | 107 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm | Total |
|---|---|---|---|---|
| China | 10 | 65 | 32 | 107 |
| Body Mass Index(kg/m^2) | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm | Total |
|---|---|---|---|---|
| Mean | 24.19 ± 3.28 | 22.90 ± 3.47 | 22.61 ± 3.29 | 22.93 ± 3.40 |
| Eastern Cooperative Oncology Group Performance Status Case Report Form at Baseline(Participants) | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm | Total |
|---|---|---|---|---|
| 0 | 7 | 22 | 9 | 38 |
| 1 | 3 | 43 | 23 | 69 |
| Number of Participants According to Primary Site of Cancer(Participants) | Safety Lead-in Phase: ENCO + CETUX | Randomized Phase: ENCO + CETUX | Randomized Phase: Control Arm | Total |
|---|---|---|---|---|
| Colon, Left | 5 | 39 | 16 | 60 |
| Colon, Right | 5 | 26 | 16 | 47 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Dec 2023, 27 months.
Results were first posted in Apr 2026, 2 years 4 months after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 27 months is below that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Encorafenib · Cetuximab